New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease
AbbVie said 22 abstracts showed sustained endoscopic benefit with SKYRIZI and disease control with RINVOQ in difficult-to-treat Crohn's patients.
- AbbVie presented 22 scientific abstracts at the American College of Gastroenterology 2026 meeting on October 11, highlighting clinical data from its inflammatory bowel disease portfolio.
- New analyses for SKYRIZI and RINVOQ aim to address the complexities of inflammatory bowel disease care that significantly burden patients living with the condition.
- The SEQUENCE study demonstrated durable efficacy with SKYRIZI through 148 weeks, while FORTIFY data showed 74.5% of patients with fistulizing Crohn's disease achieved no draining fistulas after five years of treatment.
- Real-World data from the Veterans Affairs health system showed 93.3% of patients with fistulizing disease and 76.9% with stricturing disease achieved clinical remission while remaining on RINVOQ treatment.
- "People living with IBD want treatments that meaningfully reduce the burden of their disease," said Ryan DeMasi, M.D., vice president, global medical affairs, immunology, AbbVie, reflecting the company's commitment to therapies addressing disease drivers.
21 Articles
21 Articles
Subcutaneous Risankizumab Induction Improved Outcomes in Crohn's Disease
(MedPage Today) -- Subcutaneous risankizumab (Skyrizi) induction therapy significantly improved clinical remission and endoscopic response rates in patients with moderately to severely active Crohn's disease, results from the phase III AFFIRM trial...
The pharmaceutical company AbbVie reported new results from a phase 3 clinical trial that evaluated the subcutaneous use of SKYRIZI in adults with moderate to severe active Crohn's disease, with findings reflecting improvements in indicators of intestinal inflammation.
Journal Gazette & Times-Courier
Bismarck TribuneAbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and Endoscopic Outcomes With Subcutaneous SKYRIZI® (risankizumab-rzaa) in Patients With Moderately to Severely Active Crohn's Disease
Higher rates of endoscopic remission and ulcer-free endoscopy were observed following subcutaneous SKYRIZI® (risankizumab-rzaa)treatment versus placeboiResults build on previously reported week 12 findings in which SKYRIZI achieved superiority in the co-primary endpoints of clinical remission and endoscopic response versus placeboThese…
charitonleader.com
New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease
New Phase 3 AFFIRM data show higher rates of clinical and endoscopic response in Crohn's disease patients treated with subcutaneous SKYRIZI versus placebo across all efficacy endpoints and observed subgroupsNew open-label extension analyses demonstrate sustained endoscopic outcomes over time with…
Coverage Details
Bias Distribution
- 85% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
